Overview

Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is a prospective,multi-center, open-label, randomized controlled clinical trial,aims to assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of Dual Anti-Platelet Therapy (DAPT) in patients undergoing percutaneous coronary intervention implanted sirolimus target- eluting stent with abluminal grooves containing a biodegradable polymer (Firehawk™ stent). All participants met the inclusion criteria begin taking aspirin and open-label thienopyridine therapy before index procedure, and will be 1:1 randomized to 3 months or 12 month of DAPT at index procedure.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai MicroPort Medical (Group) Co., Ltd.
Treatments:
Aspirin
Clopidogrel
Ticagrelor
Ticlopidine